Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 29

PMID 33777773

Citations 16

Authors

Jessie A Elliott

John V Reynolds

Affiliations

Soon will be listed here.

Abstract

Esophageal adenocarcinoma (EAC) represents an exemplar of obesity-associated carcinogenesis, with a progressive increase in EAC risk with increased body mass index. In this context, there is increased focus on visceral adipose tissue and associated metabolic dysfunction, including hypertension, diabetes mellitus and hyperlipidemia, or combinations of these in the metabolic syndrome. Visceral obesity (VO) may promote EAC both directly impacting on gastro-esophageal reflux disease and Barrett's esophagus, as well as reflux-independent effects, involving adipokines, growth factors, insulin resistance, and the microbiome. In this review these pathways are explored, including the impact of VO on the tumor microenvironment, and on cancer outcomes. The current evidence-based literature regarding the role of dietary, lifestyle, pharmacologic and surgical interventions to modulate the risk of EAC is explored.

Citing Articles

Global Burden of Esophageal Cancer and Its Risk Factors: A Systematic Analysis of the Global Burden of Disease Study 2019.

Ilic I, Zivanovic Macuzic I, Ravic-Nikolic A, Ilic M, Milicic V Life (Basel). 2025; 15(1).

PMID: 39859964 PMC: 11767048. DOI: 10.3390/life15010024.

Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma.

Hassan M, Johnson C, Ponna S, Scofield D, Awasthi N, von Holzen U Cancers (Basel). 2024; 16(18).

PMID: 39335147 PMC: 11430189. DOI: 10.3390/cancers16183175.

Causal effects of genetically determined metabolites and metabolite ratios on esophageal diseases: a two-sample Mendelian randomization study.

Yang H, Wang Y, Zhao Y, Cao L, Chen C, Yu W BMC Gastroenterol. 2024; 24(1):310.

PMID: 39271994 PMC: 11401347. DOI: 10.1186/s12876-024-03411-8.

Esophageal cancer global burden profiles, trends, and contributors.

Teng Y, Xia C, Cao M, Yang F, Yan X, He S Cancer Biol Med. 2024; 21(8).

PMID: 39066471 PMC: 11359494. DOI: 10.20892/j.issn.2095-3941.2024.0145.

Usefulness of the preoperative inflammation-based prognostic score and the ratio of visceral fat area to psoas muscle area on predicting survival for surgically resected adenocarcinoma of the esophagogastric junction.

Uchida S, Sohda M, Tateno K, Watanabe T, Shibasaki Y, Nakazawa N Esophagus. 2023; 21(2):157-164.

PMID: 38112929 DOI: 10.1007/s10388-023-01034-8.

References

Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal J, Montagner A . Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2019; 63(3):453-461. PMC: 6997275. DOI: 10.1007/s00125-019-05040-3. View

Vasanthakumar A, Chisanga D, Blume J, Gloury R, Britt K, Henstridge D . Sex-specific adipose tissue imprinting of regulatory T cells. Nature. 2020; 579(7800):581-585. PMC: 7241647. DOI: 10.1038/s41586-020-2040-3. View

Jankowski J, De Caestecker J, Love S, Reilly G, Watson P, Sanders S . Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018; 392(10145):400-408. PMC: 6083438. DOI: 10.1016/S0140-6736(18)31388-6. View

Li X, Paulson T, Galipeau P, Sanchez C, Liu K, Kuhner M . Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Cancer Prev Res (Phila). 2015; 8(9):845-56. PMC: 4560605. DOI: 10.1158/1940-6207.CAPR-15-0130. View

Kardassis D, Grote L, Sjostrom L, Hedner J, Karason K . Sleep apnea modifies the long-term impact of surgically induced weight loss on cardiac function and inflammation. Obesity (Silver Spring). 2013; 21(4):698-704. DOI: 10.1002/oby.20115. View

Reynolds J, Donohoe C, McGillycuddy E, Ravi N, OToole D, OByrne K . Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center. J Thorac Cardiovasc Surg. 2012; 143(5):1130-1137.e1. DOI: 10.1016/j.jtcvs.2011.12.003. View

Kassi E, Pervanidou P, Kaltsas G, Chrousos G . Metabolic syndrome: definitions and controversies. BMC Med. 2011; 9:48. PMC: 3115896. DOI: 10.1186/1741-7015-9-48. View

Rubenstein J, Dahlkemper A, Kao J, Zhang M, Morgenstern H, McMahon L . A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol. 2008; 103(6):1358-64. DOI: 10.1111/j.1572-0241.2008.01823.x. View

Galipeau P, Li X, Blount P, Maley C, Sanchez C, Odze R . NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007; 4(2):e67. PMC: 1808095. DOI: 10.1371/journal.pmed.0040067. View

10.

Anggiansah R, Sweis R, Anggiansah A, Wong T, Cooper D, Fox M . The effects of obesity on oesophageal function, acid exposure and the symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013; 37(5):555-63. DOI: 10.1111/apt.12208. View

11.

Melis M, Weber J, McLoughlin J, Siegel E, Hoffe S, Shridhar R . An elevated body mass index does not reduce survival after esophagectomy for cancer. Ann Surg Oncol. 2010; 18(3):824-31. PMC: 4623586. DOI: 10.1245/s10434-010-1336-1. View

12.

Behrens G, Jochem C, Keimling M, Ricci C, Schmid D, Leitzmann M . The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis. Eur J Epidemiol. 2014; 29(3):151-70. DOI: 10.1007/s10654-014-9895-2. View

13.

Dulak A, Stojanov P, Peng S, Lawrence M, Fox C, Stewart C . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-86. PMC: 3678719. DOI: 10.1038/ng.2591. View

14.

Mengardo V, Pucetti F, Mc Cormack O, Chaudry A, Allum W . The impact of obesity on esophagectomy: a meta-analysis. Dis Esophagus. 2018; 31(6). DOI: 10.1093/dote/dox149. View

15.

Roberts D, Dive C, Renehan A . Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2009; 61:301-16. DOI: 10.1146/annurev.med.080708.082713. View

16.

Dura P, van Veen E, Salomon J, Te Morsche R, Roelofs H, Kristinsson J . Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer. 2013; 133(7):1751-5. DOI: 10.1002/ijc.28160. View

17.

Petrick J, Hyland P, Caron P, Falk R, Pfeiffer R, Dawsey S . Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. J Natl Cancer Inst. 2018; 111(1):34-41. PMC: 6335110. DOI: 10.1093/jnci/djy082. View

18.

Singh S, Sharma A, Murad M, Buttar N, El-Serag H, Katzka D . Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11(11):1399-1412.e7. PMC: 3873801. DOI: 10.1016/j.cgh.2013.05.009. View

19.

Snider E, Compres G, Freedberg D, Khiabanian H, Nobel Y, Stump S . Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2019; 28(10):1687-1693. PMC: 6774849. DOI: 10.1158/1055-9965.EPI-19-0008. View

20.

Howard J, Cathcart M, Healy L, Beddy P, Muldoon C, Pidgeon G . Leptin and adiponectin receptor expression in oesophageal cancer. Br J Surg. 2014; 101(6):643-52. DOI: 10.1002/bjs.9469. View